• Vaccine Ontology ID: VO_0004189
• Type: DNA vaccine
• Status: Research
• Antigen: The pVR1020/oprF plasmid.
• OprF gene engineering:
  • Type: DNA vaccine construction
  • Description: The 977-bp oprF gene was cloned from P. aeruginosa PAO1 genomic DNA into the eukaryotic expression plasmid pVR1020 (Price et al., 2001).
  • Detailed Gene Information: Click Here.
• Vector: pVR1020
• Immunization Route: abdomen gene gun

• Vaccine Ontology ID: VO_0004570
• Type: DNA vaccine
• Status: Research
• Host Species as Laboratory Animal Model: Mouse
• OprF gene engineering:
  • Type: DNA vaccine construction
  • Detailed Gene Information: Click Here.
• OprI gene engineering:
  • Type: DNA vaccine construction
  • Detailed Gene Information: Click Here.
• Vector: pGACAG (Saha et al., 2006)
• Immunization Route: intramuscular electroporation

• Vaccine Ontology ID: VO_0004572
• Type: DNA vaccine
• Status: Research
• Host Species as Laboratory Animal Model: Mouse
• OprF gene engineering:
  • Type: DNA vaccine construction
  • Detailed Gene Information: Click Here.
• OprI gene engineering:
  • Type: DNA vaccine construction
  • Detailed Gene Information: Click Here.
• PcrV gene engineering:
  • Type: DNA vaccine construction
  • Detailed Gene Information: Click Here.
• pilA gene engineering:
  • Type: DNA vaccine construction
  • Detailed Gene Information: Click Here.
• Vector: pGACAG (Saha et al., 2006)
• Immunization Route: intramuscular electroporation

• Vaccine Ontology ID: VO_0004571
• Type: DNA vaccine
• Status: Research
• Host Species as Laboratory Animal Model: Mouse
• PcrV gene engineering:
  • Type: DNA vaccine construction
  • Detailed Gene Information: Click Here.
• Vector: pGACAG (Saha et al., 2006)
• Immunization Route: intramuscular electroporation

• Vaccine Ontology ID: VO_0004190
• Type: Subunit vaccine
• Status: Research
• Antigen: Recombinant OprI protein
• OprI gene engineering:
  • Type: Recombinant protein preparation
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • VO ID: VO_0000127
  • Description: 100 μl of 1.5% Al(OH)3 (Finke et al., 1990).
• Immunization Route: Intraperitoneal injection (i.p.)

• Vaccine Ontology ID: VO_0004191
• Type: Subunit vaccine
• Status: Research
• Antigen: PcrV
• PcrV gene engineering:
  • Type: Recombinant protein preparation
  • Description: PcrV was produced as a lipopolysaccharide-free histidine-tagged infusion protein in pET16b and was purified by nickel chromatography (Holder et al., 2001).
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • VO ID: VO_0000142
  • Description: 0.1 ml of incomplete Freund's adjuvant (Holder et al., 2001).
• Immunization Route: Intramuscular injection (i.m.)

• Vaccine Ontology ID: VO_0004674
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Baboon
• Preparation: Attenuated Salmonella enterica serovar Typhimurium SL3261 expressing P. aeruginosa serogroup O11 O antigen (DiGiandomenico et al., 2004).
• Immunization Route: Intramuscular injection (i.m.)

Mouse Response

• Host Strain: Pathogen Free ICR
• Vaccination Protocol: At 14-day intervals, groups of 30 mice were inoculated a total of three times in the abdomen via biolistic particle injection (Helios Gene Gun kit; Bio-Rad, Richmond, Calif.) on days 0, 14, and 28 with 2 μg of either pVR1020 (control) or pVR1020/oprF, which was used to coat 1-μm-diameter gold beads (Price et al., 2001).
• Challenge Protocol: Two weeks after the final immunization, the mice were challenged with agar beads containing the P. aeruginosa FD immunotype 4 strain. The mice were first anesthetized with an intraperitoneal injection of sodium pentobarbital and then inoculated via a tracheal incision with 50 μl of an agar bead slurry encasing approximately 7 × 10^2 CFU of P. aeruginosa (Price et al., 2001).
• Efficacy: A significant reduction in the presence of severe macroscopic lesions, as well as in the number of bacteria present in the lungs, was seen in immunized mice (Price et al., 2001).
• Description: The immunoprotective potential of the pVR1020/oprF vaccine was tested in a mouse model of chronic pulmonary infection (Price et al., 2001).

Mouse Response

• Vaccine Immune Response Type: VO_0003057
• Efficacy: Monovalent DNA vaccination targeting OprF/OprI could protect 80% of mice 4 days p.i. On the other hand, 70% of mice immunized with the control plasmid, PilA vaccine, or multivalent vaccine via GG were dead within 5 days p.i. (p < 0.01) (Saha et al., 2006).

Mouse Response

• Vaccine Immune Response Type: VO_0003057
• Efficacy: All mice vaccinated with multivalent DNA via imEPT survived for more than 10 days p.i. with PAK. On the other hand, 70% of mice immunized with the control plasmid, PilA vaccine, or multivalent vaccine via GG were dead within 5 days p.i. (p < 0.01) (Saha et al., 2006).

Mouse Response

• Vaccine Immune Response Type: VO_0003057
• Efficacy: Monovalent DNA vaccination targeting PcrV could protect 80% of mice 4 days p.i. On the other hand, 70% of mice immunized with the control plasmid, PilA vaccine, or multivalent vaccine via GG were dead within 5 days p.i. (p < 0.01) (Saha et al., 2006).

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: Female BALB/c mice, 12 to 16 weeks old, received 100 μl (27 ,ug) of OprI suspended in 100 μl of 1.5% Al(OH)3 intraperitoneally on days 0, 14, 35, and 63. Controls received Al(OH)3 only (Finke et al., 1990).
• Challenge Protocol: mice were challenged intraperitoneally 10 days after the last immunization with 200 μl of a P. aeruginosa serogroup 6 suspension. Mice vaccinated with recombinant OprI received 6 x 10^6 to 1 x 10^8 living organisms each. (Finke et al., 1990).
• Efficacy: Recombinant OprI protein was used to immunize mice, and was found to be protective against a challenge with a four- to fivefold 50% lethal dose of P. aeruginosa (Finke et al., 1990).

Mouse Response

• Host Strain: CF-1
• Vaccination Protocol: On day 0, groups of 10 female CF-1 mice weighing 22 to 25 g were immunized intramuscularly in the hind leg (10 μg of immunogen in 0.1 ml of incomplete Freund's adjuvant), followed by a booster dose (10 μg in saline) without adjuvant on day 14 (Holder et al., 2001).
• Challenge Protocol: Using the burned mouse model, mice were challenged by one of three strains of P. aeruginosa (Holder et al., 2001).
• Efficacy: Burned Pseudomonas aeruginosa-infected mice immunized against PcrV, a type III virulence system translocating protein, showed significantly enhanced survival compared to controls (Holder et al., 2001).

Mouse Response

• Vaccination Protocol: For oral vaccination, mice were fed 100 μl of either PBS or the Salmonella vector and vaccine strains (1 × 10^9 to 5 × 10^9 CFU) by intragastric gavage. Oral inoculation was repeated once per week for a total of 4 weeks. For i.p. vaccination, mice were inoculated with a single dose of either PBS or each Salmonella strain (10^6 CFU) (DiGiandomenico et al., 2004).
• Vaccine Immune Response Type: VO_0003057
• Challenge Protocol: Mice were challenged with P. aeruginosa strains 9882-80 (serogroup O11) and 6294 (serogroup O6) (DiGiandomenico et al., 2004).
• Efficacy: Orally vaccinated mice with an O11 strain (9882-80) at 6 and 12 times the 50% lethal dose showed increased survival in mice that received the vaccine compared to phosphate-buffered saline (PBS)- and vector-treated controls; no difference in survival was seen with a heterologous strain, 6294 (serogroup O6). In addition, significant protection against 9882-80 was not observed in i.p. vaccinated animals (DiGiandomenico et al., 2004).